Polyfunctional t-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Tran, Eric ^a,b   Nielsen, Julie S ^b,c   Wick, Darin A ^b   Ng, Alvin V ^b   Johnson, Lisa D S ^b   Nesslinger, Nancy J ^b   McMurtrie, Elissa ^b   Webb, John R ^a,b   Nelson, Brad H ^a,b,c  

^a UNIVERSITY OF VICTORIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 9; KI 67 ANTIGEN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLATELET DERIVED GROWTH FACTOR BB; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; INTERLEUKIN DERIVATIVE;

ADULT; AGED; ARTICLE; ASCITES CELL; ASCITES FLUID; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; OVARY CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; BLOOD; CELL PROLIFERATION; CYTOLOGY; METABOLISM; MIDDLE AGED; OVARY TUMOR; T LYMPHOCYTE;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-2; INTERLEUKINS; MIDDLE AGED; OVARIAN NEOPLASMS; T-LYMPHOCYTES;

EID: 78650973754     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015625     Document Type: Article

References (68)

1. Nelson BH (2008) The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev 222: 101-116.
2. Chu CS, Kim SH, June CH, Coukos G (2008) Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 8: 243-257.
3. Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, et al. (2007) Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3(+)CD56(+) cells with platinum resistance. Gynecol Oncol.
4. Gaffen SL (2009) Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9: 556-567.
5. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, et al. (2009) Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments. Blood.
6. Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
7. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ (2005) Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54: 369-377.
8. Yang T, Wall EM, Milne K, Theiss P, Watson P, et al. (2007) CD8+ T cells induce complete regression of advanced ovarian cancers by an Interleukin (IL)- 2/IL-15 dependent mechanism. Clin Cancer Res 13: 7172-7180.
9. Hirte HW, Clark DA, O'Connell G, Rusthoven J, Mazurka J (1992) Reversal of suppression of lymphokine-activated killer cells by transforming growth factorbeta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody. Cell Immunol 142: 207-216.
10. Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, et al. (1995) Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid. J Soc Gynecol Investig 2: 762-771.
11. DeCesare SL, Michelini-Norris B, Blanchard DK, Barton DP, Cavanagh D, et al. (1995) Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system. Gynecol Oncol 57: 86-95.
12. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, et al. (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 115: 1616-1626.
13. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
14. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, et al. (2007) Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 204: 1405-1416.
15. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, et al. (2008) Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131.
16. Beveridge NE, Price DA, Casazza JP, Pathan AA, Sander CR, et al. (2007) Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 37: 3089-3100.
17. Elvang T, Christensen JP, Billeskov R, Thi Kim Thanh, Hoang T, Holst P, et al. (2009) CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination. PLoS ONE 4: e5139.
18. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.
19. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
20. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, et al. (2008) Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38: 350-363.
21. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473-2485.
22. Almeida JR, Sauce D, Price DA, Papagno L, Shin SY, et al. (2009) Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV suppressive activity. Blood 113: 6351-6360.
23. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, et al. (2009) Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113: 3978-3989.
24. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, et al. (2008) Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 82: 3391-3404.
25. Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, et al. (2007) Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 81: 12071-12076.
26. Bansal A, Jackson B, West K, Wang S, Lu S, et al. (2008) Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol 82: 6458-6469.
27. Valor L, Navarro J, Carbone J, Rodriguez-Sainz C, Gil J, et al. (2008) Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1- specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine 26: 2738-2745.
28. Winstone N, Guimaraes-Walker A, Roberts J, Brown D, Loach V, et al. (2009) Increased detection of proliferating, polyfunctional, HIV-1-specific T cells in DNA-modified vaccinia virus Ankara-vaccinated human volunteers by cultured IFN-gamma ELISPOT assay. Eur J Immunol 39: 975-985.
29. Lichterfeld M, Yu XG, Waring MT, Mui SK, Johnston MN, et al. (2004) HIV- 1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood 104: 487-494.
30. Badr G, Bedard N, Abdel-Hakeem MS, Trautmann L, Willems B, et al. (2008) Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 82: 10017-10031.
31. Yi JS, Du M, Zajac AJ (2009) A Vital Role for Interleukin-21 in the Control of a Chronic Viral Infection. Science 324: 1572-1576.
32. Imai N, Ikeda H, Tawara I, Shiku H (2009) Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. Eur J Immunol 39: 241-253.
33. Imai N, Ikeda H, Tawara I, Wang L, Wang L, et al. (2009) Glucocorticoidinduced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8 T cells with tumor regression. Cancer Sci 100: 1317-1325.
34. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, et al. (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105: 20410-20415.
35. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, et al. (2009) Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 106: 3360-3365.
36. Perales MA, Yuan J, Powel S, Gallardo HF, Rasalan TS, et al. (2008) Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 16: 2022-2029.
37. Watford WT, Hissong BD, Bream JH, Kanno Y, Muul L, et al. (2004) Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 202: 139-156.
38. Zeng R, Spolski R, Casas E, Zhu W, Levy DE, et al. (2007) The molecular basis of IL-21-mediated proliferation. Blood 109: 4135-4142.
39. Iwai Y, Hemmi H, Mizenina O, Kuroda S, Suda K, et al. (2008) An IFNgamma- IL-18 signaling loop accelerates memory CD8+ T cell proliferation. PLoS ONE 3: e2404.
40. Carroll RG, Carpenito C, Shan X, Danet-Desnoyers G, Liu R, et al. (2008) Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS One 3: e3289.
41. Okamoto I, Kohno K, Tanimoto T, Ikegami H, Kurimoto M (1999) Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. J Immunol 162: 3202-3211.
42. Cullen SP, Brunet M, Martin SJ. Granzymes in cancer and immunity. Cell Death Differ 17: 616-623.
43. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, et al. (2010) The Inducible Costimulator (ICOS) Is Critical for the Development of Human TH17 Cells. Sci Transl Med 2: 55-78.
44. Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95-109.
45. Ahn HJ, Maruo S, Tomura M, Mu J, Hamaoka T, et al. (1997) A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma. Journal of Immunology 159: 2125-2131.
46. Smeltz RB, Chen J, Hu-Li J, Shevach EM (2001) Regulation of interleukin (IL)- 18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/ Th2 differentiation. Critical downregulatory role of IL-4. J Exp Med 194: 143-153.
47. Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH (2007) Immunotherapy ofcancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7: 1705-1721.
48. Xu D, Chan WL, Leung BP, Hunter D, Schulz K, et al. (1998) Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. Journal of Experimental Medicine 188: 1485-1492.
49. Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 73: 213-224.
50. Nelson BH, Willerford DM (1998) Biology of the interleukin-2 receptor. Adv Immunol 70: 1-81.
51. Gollob JA, Schnipper CP, Murphy EA, Ritz J, Frank DA (1999) The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. Journal of Immunology 162: 4472-4481.
52. Nakahira M, Ahn HJ, Park WR, Gao P, Tomura M, et al. (2002) Synergy of IL- 12 and IL-18 for IFN-gamma gene expression: IL-12-induced STAT4 contributes to IFN-gamma promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J Immunol 168: 1146-1153.
53. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, et al. (2010) A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 59: 293-301.
54. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, et al. (1997) Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 15: 3399-3407.
55. Recchia F, Di Orio F, Candeloro G, Guerriero G, Piazze J, et al. Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study. Gynecol Oncol 116: 202-207.
56. Recchia F, Saggio G, Cesta A, Candeloro G, Nuzzo A, et al. (2005) Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer. Int J Oncol 27: 1039-1046.
57. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, et al. (2007) Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease,1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5: 66.
58. Hurteau JA, Blessing JA, DeCesare SL, Creasman WT (2001) Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol 82: 7-10.
59. Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, et al. (2009) A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 115: 859-868.
60. Robertson MJ, Kirkwood JM, Logan TF, Koch KM, Kathman S, et al. (2008) A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer. Clin Cancer Res 14: 3462-3469.
61. Robertson MJ, Mier JW, Logan T, Atkins M, Koon H, et al. (2006) Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res 12: 4265-4273.
62. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, et al. (2009) Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 15: 2123-2129.
63. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, et al. (2007) An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13: 3630-3636.
64. Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, et al. (2008) Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26: 2034-2039.
65. Osaki T, Peron JM, Cai Q, Okamura H, Robbins PD, et al. (1998) IFN-gammainducing factor/IL-18 administration mediates IFN-gamma- and IL-12- independent antitumor effects. Journal of Immunology 160: 1742-1749.
66. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, et al. (2000) Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood 96: 1465-1473.
67. Osaki T, Hashimoto W, Gambotto A, Okamura H, Robbins PD, et al. (1999) Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene therapy 6: 808-815.
68. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.